<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558947</url>
  </required_header>
  <id_info>
    <org_study_id>PC-AGC-01</org_study_id>
    <nct_id>NCT01558947</nct_id>
  </id_info>
  <brief_title>Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer</brief_title>
  <official_title>Peri-operative Chemotherapy With ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine + Cisplatin) in the Treatment of Advanced Gastric Cancer: a Randomized, Multicenter, Parallel Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the effect of perioperative
      chemotherapy in the treatment of advanced gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the security and the relapse-free survival time/rate(1,2,3 yrs) of perioperative
      chemotherapy with ECX (epirubicin + cisplatin + capecitabine) and XP (capecitabine +
      cisplatin）in advanced gastric cancer
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the relapse-free survival time/rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy with ECX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy with ECX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy with XP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy with XP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peri-operative chemotherapy of ECX</intervention_name>
    <description>Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4~6 weeks after surgery.</description>
    <arm_group_label>chemotherapy with ECX</arm_group_label>
    <other_name>ECX chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peri-operative chemotherapy of XP</intervention_name>
    <description>Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4~6 weeks after surgery.</description>
    <arm_group_label>chemotherapy with XP</arm_group_label>
    <other_name>XP chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged 18 to 70 years old.

          -  The preoperative evaluation: gastric cancer patients, ≥ T2 or N +; or staging II,
             IIIA, IIIB.

          -  Karnofsky score ≥ 70, life expectancy &gt; 6 months.

          -  Endoscopic biopsy diagnosis of gastric cancer, excluding non-Hodgkin's lymphoma,
             leiomyosarcoma and other mesenchymal tumors.

          -  the blood and biochemical indicators of the subjects must meet the following criteria:
             Hb ≥ 9 g / dl; WBC ≥ 4,000 / mm3, ≤ 12000 / mm3; PLT ≥ 100,000/mm3; GOT, GPT within
             twice the institutional limit,serum total bilirubin &lt; 1.5 times the upper limit of
             normal, serum creatinine&lt; 1.25 times the upper limit of normal and creatinine
             clearance rate ≥ 60ml/min, LVEF ≥ 60%.

          -  have not received prior chemotherapy, radiotherapy and biological therapy.

          -  signed informed consent.

          -  must accept the standard D2 or D2 + radical gastrectomy.

          -  with good compliance.

        Exclusion Criteria:

          -  pregnancy, breast-feeding women.

          -  allergy with chemotherapy drugs or metabolic disorder.

          -  the history of organ transplants (including bone marrow transplantation and autologous
             peripheral stem cell transplantation).

          -  had long received systemic steroid treatment (Note: short-term users of withdrawal &gt; 2
             weeks can be selected.)

          -  The existence of the peripheral nervous system disorders or significant neurological
             disorders and a history of central nervous system disorders.

          -  patients with severe infection requires treatment.

          -  patients associated with dysphagia, active peptic ulcer, incompleteness intestinal
             obstruction, active gastrointestinal bleeding, perforation.

          -  severe liver disease (such as cirrhosis), kidney disease, respiratory disease or
             uncontrollable diabetes.

          -  with other malignancies which were not cured.

          -  EKG abnormalities or heart disease with apparent clinical symptoms, including
             congestive heart failure, coronary heart disease with symptoms, uncontrollable
             arrhythmia, hypertension, and heart attack within 12 months or III or IV grade
             myocardial infarction. Coronary heart disease with symptoms, uncontrollable
             arrhythmia, hypertension, and heart attack within 12 months or III or IV grade
             myocardial infarction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiangdong Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiangdong Cheng, MD</last_name>
    <phone>+86 571 88122516</phone>
    <email>abdsurg@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiangdong Cheng, MD</last_name>
      <phone>+86 571 88122516</phone>
      <email>abdsurg@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>xiangdong Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>March 18, 2012</last_update_submitted>
  <last_update_submitted_qc>March 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>Peri-operative chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

